GlobeNewswire by notified

Transactions in Connection with Share Buy-back Program

Share

Company Announcement

COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.

The share buy-back program is expected to be completed no later than December 16, 2024.

The following transactions were executed under the program from April 29, 2024 to May 3, 2024:

Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)
Accumulated through
last announcement
602,8181,222,541,085.50
April 29, 2024XCSE14,5111,972.14
CEUX9,4211,972.17
AQEU1,1301,970.30
TQEX1,3981,972.93
Total26,4601,972.1252,182,205.24
April 30, 2024XCSE6,2281,960.07
CEUX3,7501,961.20
AQEU7391,955.11
TQEX9341,957.14
Total11,6511,959.8922,834,630.62
May 1, 2024XCSE15,7231,955.74
CEUX11,4531,956.58
AQEU1,2551,955.75
TQEX1,8881,955.90
Total30,3191,956.0659,305,922.61
May 2, 2024XCSE5,6071,961.05
CEUX5,4231,960,91
AQEU7291,959.67
TQEX8521,964.18
Total12,6111,961.1224,731,713.33
May 3, 2024XCSE2,8492,044.16
CEUX2,484      2,047.92
AQEU1832,036.63
TQEX1352,043.76
Total5,6512,045.5611,559,439.78
Total86,692170,613,911.58
Accumulated under the program689,5101,393,154,997.08

Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 1,538,648 shares as treasury shares, corresponding to 2.33% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 22 dated March 15, 2024.

About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies, and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S., and Tokyo, Japan. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect®and KYSO®.

Company Announcement no. 34
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Publication of a Company Description30.5.2024 11:38:20 CEST | Press release

Kaldvík (Ice Fish Farm) has published a Company Description in relation to the admission to trading of the Company's Affiliated Shares on Nasdaq First North Growth Market Iceland. The Company Description, dated 24 May 2024 is attached. Nasdaq First North Growth Market Disclaimer Nasdaq First North Growth Market is a registered SME growth market, in accordance with the Directive on Markets in Financial Instruments (EU 2014/65) as implemented in the national legislation of Denmark, Finland, Iceland and Sweden, operated by an exchange within the Nasdaq group. Issuers on Nasdaq First North Growth Market are not subject to all the same rules as issuers on a regulated main market, as defined in EU legislation (as implemented in national law). Instead, they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in an issuer on Nasdaq First North Growth Market may therefore be higher than investing in an issuer on the main market.

Selskabsmeddelelse nr. 6, 2023/2430.5.2024 11:15:00 CEST | pressemeddelelse

Investeringsselskabet Luxor A/S’ bestyrelse har dags dato godkendt halvårsrapport pr. 31. marts 2024. 2. kvartal 2023/24: Basisindtjeningen er kr. 10,0 mio. (kr. 12,2 mio.). Resultat før skat er kr. 14,1 mio. (kr. 12,1 mio.). Kvartalets resultat før skat er kr. 4,1 mio. højere end basisindtjeningen, hvilket skyldes:kr. 2,5 mio. fra dagsværdiregulering af finansielle aktiver. kr. 1,6 mio. fra dagsværdiregulering af renteswaps og gæld til realkreditinstitutter. Halvåret 2023/24: Basisindtjeningen er kr. 21,9 mio. (kr. 21,7 mio.). Koncernens resultat før skat er kr. 12,9 mio. (kr. 20,3 mio.). Halvårets resultat er kr. 9,0 mio. lavere end basisindtjeningen, hvilket skyldes: kr. 5,3 mio. fra dagsværdiregulering af finansielle aktiver. kr. -14,3 mio. fra dagsværdiregulering af renteswaps og gæld til realkreditinstitutter samt omkostninger til optagelse af realkreditlån. Forventet basisindtjening 2023/24: For regnskabsåret 2023/24 forventes på indeværende tidspunkt en basisindtjening i niveau

Prosafe SE: Prosafe issued Conditional Letter of Intent for Safe Boreas30.5.2024 11:08:50 CEST | Press release

Oslo, 30 May 2024 Prosafe has been issued a Conditional Letter of Intent (CLoI) for the Safe Boreas to provide gangway connected operations to support a project off the coast of Western Australia. The CLoI is conditional upon execution of a final contract. The firm duration of the contract linked to the CLoI is 15 months with up to six months of options. The Safe Boreas will mobilise from the North Sea within Q2 2025. Safe Boreas will undergo its five-yearly special periodic survey and other maintenance works prior to commencement of the contract. The value of the contract linked to the CLoI is approximately USD 75 million to USD 100 million depending on options. The Safe Boreas is one of the world’s most advanced and versatile semi-submersible DP-3 accommodation vessels and complies with stringent rules in Australia, Norway and UK. Single person cabins, extensive recreation facilities, combined with a large deck area, cranes and passive motion compensated gangway will ensure the highe

Fortuna publishes its 2023 Sustainability Report30.5.2024 11:00:00 CEST | Press release

VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM | TSX: FVI) is pleased to announce the publication of its sixth annual sustainability report which details the Company’s performance on key environmental, social, and governance (ESG) indicators during 2023. The report also includes dedicated sections on Fortuna’s sustainability management and initiatives at each of the Company’s operating mines as well as the contributions made within the countries that host our operations in the Latin America and West Africa regions. Also included is an ESG data section containing disclosure under sustainability accounting Standards Board (SASB) Metals and Mining Standard, the Task Force on Climate-Related Financial Disclosures Recommendations (TCFD), and the Global Reporting Initiative (GRI) standard. Jorge A. Ganoza, President and CEO of Fortuna, commented, “In 2023, we have made significant progress with respect to tailings management, climate change

Scape Technologies A/S – forløb af ordinær generalforsamling30.5.2024 10:57:49 CEST | pressemeddelelse

Nasdaq First North Growth Market Denmark Selskabsmeddelelse nr. 69/2024 Odense, 30. maj 2024 Scape Technologies A/S – forløb af ordinær generalforsamling Der er i dag afholdt ordinær generalforsamling i Scape Technologies A/S med følgende dagsorden: 1. Valg af dirigent 2. Fremlæggelse af den reviderede årsrapport til godkendelse 3. Beslutning om anvendelse af overskud eller dækning af underskud i henhold til den godkendte årsrapport 4. Valg af medlemmer til bestyrelsen 5. Valg af revisor 6. Eventuelle forslag fra bestyrelse og aktionærer Forslag om afnotering fra Nasdaq First North Growth Market DenmarkForslag om nedsættelse af aktiekapitalen Selskabets aktionærer godkendte årsrapporten og den foreslåede resultatdisponering. Bestyrelsens medlemmer blev genvalgt. Selskabets revisor, Deloitte Statsautoriseret Revisionspartnerskab, blev genvalgt. Generalforsamling godkendte afnotering af selskabets aktier fra Nasdaq First North Growth Market Denmark. Selskabet vil nu anmode Nasdaq First N

HiddenA line styled icon from Orion Icon Library.Eye